Phenylketonuria Market Size To Hit US$ 4,338.0 Million By 2033
According to IMARC Group’s latest report, titled “Phenylketonuria Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033”, The 7 major phenylketonuria markets reached a value of US$ 822.5 Million in 2022. Looking forward, IMARC Group expects the 7MM to reach US$ 4,338.0 Million by 2033, exhibiting a growth rate (CAGR) of 16.3% during 2023-2033.This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the market in any form.
Industry Definition and Application:
Phenylketonuria is an uncommon genetic disorder characterized by the buildup of phenylalanine, an amino acid, in the body. This condition arises due to changes in the phenylalanine hydroxylase (PAH) gene, which codes for the enzyme required for phenylalanine metabolism. In infants, symptoms can range from mild to severe, including a musty odor in breath, urine, or skin, a small head size, hyperactivity, delayed development, seizures, and skin rashes. Older children and adults may experience intellectual disabilities, learning difficulties, behavioral problems like anxiety and depression, and tremors. Newborn screening, blood workups, and genetic testing are commonly used for diagnosis. Additional tests such as a triple-quadrupole mass spectrometer, urinalysis, and the Guthrie card bacterial inhibition assay may be performed to confirm the condition.
Request for a Free Sample Copy of this Report: https://www.imarcgroup.com/phenylketonuria-market/requestsample
What are the growth prospects and trends in the industry?
The phenylketonuria market is being driven by the increasing incidence of genetic mutations and the growing demand for effective medications to address this condition. Additionally, the market is propelled by the widespread adoption of drug formulations like sapropterin dihydrochloride and pegvaliase-pqpz, which help lower blood phenylalanine levels in patients. The introduction of innovative diagnostic techniques, such as tandem mass spectrometry and high-performance liquid chromatography, which help in accurately measuring blood phenylalanine levels and differentiating phenylketonuria from other conditions, is further supporting market growth.
Moreover, key industry players are exploring gene therapy options to restore phenylalanine hydroxylase activity, thereby preventing neurological and cognitive complications associated with the disease, leading to a positive market outlook. Additionally, the ongoing development of various biomarkers like brain-derived neurotrophic factor (BDNF) and oxidative stress markers is expected to drive advancements in phenylketonuria diagnosis and monitoring in the future.
Countries Covered:
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the phenylketonuria market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the phenylketonuria market
- Reimbursement scenario in the market
- In-market and pipeline drugs
This report also provides a detailed analysis of the current surgical site infections marketed drugs and late-stage pipeline drugs.
In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug overview
- Mechanism of action
- Regulatory status
- Clinical trial results
- Drug uptake and market performance
Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: \https://www.imarcgroup.com/request?type=report&id=7505&flag=C
Competitive Landscape With Key Players:
The competitive landscape of the surgical site infections market has been studied in the report with the detailed profiles of the key players operating in the market.
Key Highlights of the Report:
- Market Performance (2017-2022)
- Market Outlook (2023-2033)
- Market Trends
- Market Drivers and Success Factors
- Impact of COVID-19
- Value Chain Analysis
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Media Contact:
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: sales@imarcgroup.com
Phone: +1-631-791-1145
Address: 134 N 4th St
City: Brooklyn
State: NY
Country: United States
Website: https://www.imarcgroup.com/
